Work

Clinical characteristics and treatment outcomes in patients with histiocytic neoplasms harboring class 3 MAP2K1 mutations, including treatment with the ERK inhibitor ulixertinib.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.e19081

Authors: Eli L. Diamond, Mariko Yabe, Kseniya Petrova-Drus, Marc Rosenblum, Veronica Rotemberg, Mario E. Lacouture, Raajit Rampal, Jasmine Francis, Deb Knoerzer, Brent Kreider, Omar Ibrahim Abdel-Wahab, Benjamin Heath Durham

Institution: Memorial Sloan Kettering Cancer Center

Language: English

Topic: Histiocytic Disorders and Treatments

Subfield: Physiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4281724474

Cites:

Cited by: 4

Related to: 10